Expanding clinical R&D pipeline

Oryzon presented more granular data from Phase I/IIa in acute leukaemia at the American Society of Hematology (ASH) meeting after the positive headline results had been announced earlier. ORY-1001’s further development is now in Roche’s hands, which also initiated a Phase I trial in a new indication small cell lung cancer (SCLC). Recently Oryzon released preclinical data supporting ORY-2001’s potential in multiple sclerosis (MS), which we now include in our valuation. All these developments led to an increase in our Oryzon’s valuation to €250m.